{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:06:09Z","timestamp":1793419569504,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006418","name":"Brown University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.conctc.2024.101333","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T16:02:06Z","timestamp":1721491326000},"page":"101333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-712X","authenticated-orcid":false,"given":"Erica","family":"Eaton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Gully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-2336","authenticated-orcid":false,"given":"Mollie","family":"Monnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-6178","authenticated-orcid":false,"given":"Michael S.","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina L.","family":"Haass-Koffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.conctc.2024.101333_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1176\/ps.2010.61.6.589","article-title":"Reintegration problems and treatment interests among Iraq and Afghanistan combat veterans receiving VA medical care","volume":"61","author":"Sayer","year":"2010","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.drugalcdep.2010.11.027","article-title":"Substance use disorders in Iraq and Afghanistan veterans in VA healthcare, 2001\u20132010: implications for screening, diagnosis and treatment","volume":"116","author":"Seal","year":"2011","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jts.20434","article-title":"The impact of reported direct and indirect killing on mental health symptoms in Iraq war veterans","volume":"23","author":"Maguen","year":"2010","journal-title":"J. Trauma Stress"},{"issue":"3","key":"10.1016\/j.conctc.2024.101333_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1037\/a0019236","article-title":"The impact of PTSD, depression, and substance use disorders on disease burden and health care utilization among OEF\/OIF veterans","volume":"2","author":"Possemato","year":"2010","journal-title":"Psychol. Trauma Theor. Res. Pract. Pol."},{"issue":"12","key":"10.1016\/j.conctc.2024.101333_bib5","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/da.20907","article-title":"Prolonged exposure therapy: past, present, and future","volume":"28","author":"Foa","year":"2011","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.conctc.2024.101333_bib6","series-title":"Cognitive Processing Therapy for PTSD: A Comprehensive Manual","author":"Resick","year":"2016"},{"key":"10.1016\/j.conctc.2024.101333_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fnbeh.2018.00258","article-title":"Treating PTSD: a review of evidence-based psychotherapy interventions","volume":"12","author":"Watkins","year":"2018","journal-title":"Front. Behav. Neurosci."},{"issue":"5","key":"10.1016\/j.conctc.2024.101333_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jama.2015.8370","article-title":"Psychotherapy for military-related PTSD: a review of randomized clinical trials","volume":"314","author":"Steenkamp","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.conctc.2024.101333_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jama.2019.20825","article-title":"First-line psychotherapies for military-related PTSD","volume":"323","author":"Steenkamp","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.conctc.2024.101333_bib10","first-page":"CD003388","article-title":"Psychological therapies for chronic post\u2010traumatic stress disorder (PTSD) in adults","volume":"2013","author":"Bisson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/tra0000062","article-title":"Time course of treatment dropout in cognitive behavioral therapies for posttraumatic stress disorder","volume":"8","author":"Gutner","year":"2016","journal-title":"Psychol. Trauma Theor. Res. Pract. Pol."},{"issue":"12","key":"10.1016\/j.conctc.2024.101333_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/02698811231200880","article-title":"Treating posttraumatic stress disorder and alcohol use disorder comorbidity: current pharmacological therapies and the future of MDMA-integrated psychotherapy","volume":"37","author":"Gully","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.conctc.2024.101333_bib13","article-title":"Project harmony: a systematic review and network meta-analysis of psychotherapy and pharmacologic trials for comorbid posttraumatic stress, alcohol, and other drug use disorders","author":"Hien","year":"2023","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.conctc.2024.101333_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.conctc.2024.101333_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","article-title":"The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals","volume":"57","author":"Kamilar-Britt","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.conctc.2024.101333_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.psyneuen.2014.04.006","article-title":"Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans","volume":"46","author":"Kirkpatrick","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1016\/j.conctc.2024.101333_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hup.348","article-title":"Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies","volume":"16","author":"Liechti","year":"2001","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"12","key":"10.1016\/j.conctc.2024.101333_bib18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","article-title":"Is ecstasy an \u2018empathogen\u2019? Effects of MDMA on prosocial feelings and identification of emotional states in others","volume":"68","author":"Bedi","year":"2010","journal-title":"Biol. Psychiatr."},{"issue":"8","key":"10.1016\/j.conctc.2024.101333_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biopsych.2013.12.015","article-title":"The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level\u2013dependent resting state functional connectivity","volume":"78","author":"Carhart-Harris","year":"2015","journal-title":"Biol. Psychiatr."},{"issue":"12","key":"10.1016\/j.conctc.2024.101333_bib20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/0269881116663120","article-title":"The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants?","volume":"30","author":"Bershad","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.conctc.2024.101333_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0091-3057(91)90137-Q","article-title":"Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate","volume":"39","author":"Gough","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"issue":"5","key":"10.1016\/j.conctc.2024.101333_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0006-2952(87)90729-5","article-title":"In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain","volume":"36","author":"Schmidt","year":"1987","journal-title":"Biochem. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.conctc.2024.101333_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000253551","article-title":"Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users","volume":"60","author":"Parrott","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.conctc.2024.101333_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fpsyt.2017.00146","article-title":"The non-peptide arginine-vasopressin v1a selective receptor antagonist, SR49059, blocks the rewarding, prosocial, and anxiolytic effects of 3,4-methylenedioxymethamphetamine and its derivatives in zebra fish","volume":"8","author":"Ponzoni","year":"2017","journal-title":"Front. Psychiatr."},{"issue":"3","key":"10.1016\/j.conctc.2024.101333_bib26","first-page":"846","article-title":"3, 4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions","volume":"297","author":"Bankson","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0091-3057(95)02135-3","article-title":"Role of 5-HT in stress, anxiety, and depression","volume":"54","author":"Graeff","year":"1996","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.conctc.2024.101333_bib28","series-title":"Pharmacology and Toxicology of Amphetamine and Related Designer Drugs","first-page":"101","article-title":"Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs","volume":"94","author":"Gold","year":"1989"},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.npp.1301555","article-title":"Neural mechanisms of extinction learning and retrieval","volume":"33","author":"Quirk","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.conctc.2024.101333_bib30","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/npp.2014.80","article-title":"A window into the intoxicated mind? Speech as an index of psychoactive drug effects","volume":"39","author":"Bedi","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.conctc.2024.101333_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/17470910802649470","article-title":"Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration","volume":"4","author":"Dumont","year":"2009","journal-title":"Soc. Neurosci."},{"key":"10.1016\/j.conctc.2024.101333_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2013.11.030","article-title":"MDMA decreases the effects of simulated social rejection","volume":"117","author":"Frye","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.conctc.2024.101333_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0893-133X(00)00130-5","article-title":"3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans","volume":"23","author":"Gamma","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conctc.2024.101333_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1124\/pr.55.3.3","article-title":"The pharmacology and clinical pharmacology of 3,4methylenedioxymethamphetamine (MDMA, \u2018\u2018ecstasy","author":"Green","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.conctc.2024.101333_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.004","article-title":"MDMA and PTSD treatment: \u2018PTSD: from novel pathophysiology to innovative therapeutics","volume":"649","author":"Sessa","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.conctc.2024.101333_bib36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0006-3223(99)00219-X","article-title":"Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder","volume":"46","author":"Southwick","year":"1999","journal-title":"Biol. Psychiatr."},{"issue":"9","key":"10.1016\/j.conctc.2024.101333_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.138","article-title":"3, 4-Methylenedioxymethamphetamine facilitates fear extinction learning","volume":"5","author":"Young","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.conctc.2024.101333_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2020.10.001","article-title":"Psychedelics as a novel approach to treating autoimmune conditions","volume":"228","author":"Thompson","year":"2020","journal-title":"Immunol. Lett."},{"issue":"11","key":"10.1016\/j.conctc.2024.101333_bib39","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.conctc.2024.101333_bib40","series-title":"Trauma and Substance Abuse: Causes, Consequences, and Treatment of Comorbid Disorders","first-page":"29","article-title":"Psychosocial models of functional associations between posttraumatic stress disorder and substance use disorder","author":"Stewart","year":"2003"},{"issue":"6","key":"10.1016\/j.conctc.2024.101333_bib41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/0269881115581962","article-title":"Intimate insight: MDMA changes how people talk about significant others","volume":"29","author":"Baggott","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.conctc.2024.101333_bib42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/0269881114542454","article-title":"Differential effects of MDMA and methylphenidate on social cognition","volume":"28","author":"Schmid","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.conctc.2024.101333_bib43","first-page":"26","article-title":"Treating PTSD with MDMA-Assisted Psychotherapy: product development status and proposed design for phase 3 clinical trials","volume":"26","author":"Emerson","year":"2016","journal-title":"MAPS Bull. Winter"},{"issue":"4","key":"10.1016\/j.conctc.2024.101333_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study","volume":"27","author":"Mithoefer","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b13,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.conctc.2024.101333_bib48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial","volume":"32","author":"Ot\u2019alora","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.conctc.2024.101333_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.conctc.2024.101333_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1176\/appi.focus.23021011","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"21","author":"Mitchell","year":"2023","journal-title":"Focus"},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/18744737112059990005","article-title":"Can MDMA play a role in the treatment of substance abuse?","volume":"6","author":"Jerome","year":"2013","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.conctc.2024.101333_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","article-title":"Subjective reports of the effects of MDMA in a clinical setting","volume":"18","author":"Greer","year":"1986","journal-title":"J. Psychoact. Drugs"},{"issue":"4","key":"10.1016\/j.conctc.2024.101333_bib53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3922\/j.psns.2009.1.12","article-title":"Alcohol Use Disorders Identification Test (AUDIT): an updated systematic review of psychometric properties","volume":"2","author":"De Meneses-Gaya","year":"2009","journal-title":"Psychol. Neurosci."},{"key":"10.1016\/j.conctc.2024.101333_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109356","article-title":"The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD","volume":"233","author":"Nicholas","year":"2022","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.conctc.2024.101333_bib56","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00213-024-06598-6","article-title":"In the new era of psychedelic assisted therapy: a systematic review of study methodology in randomized controlled trials","volume":"241","author":"Soliman","year":"2024","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.conctc.2024.101333_bib57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75706-1","article-title":"MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study","volume":"10","author":"Wolfson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.conctc.2024.101333_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","article-title":"MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD","volume":"149","author":"Brewerton","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.conctc.2024.101333_bib60","series-title":"Meas. Alcohol Consum. Psychosoc. Biochem. Methods Totowa NJ","first-page":"41","article-title":"Timeline follow-back: a technique for assessing selfreported ethanol consumption","author":"Sobell","year":"2007"},{"key":"10.1016\/j.conctc.2024.101333_bib61","volume":"6","author":"Weathers","year":"2013"},{"issue":"11","key":"10.1016\/j.conctc.2024.101333_bib62","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA\u2010Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.conctc.2024.101333_bib63","series-title":"Columbia-suicide severity rating scale","author":"Posner","year":"2016"},{"key":"10.1016\/j.conctc.2024.101333_bib64","doi-asserted-by":"crossref","DOI":"10.47626\/1516-4446-2021-1893","article-title":"Inflammatory cytokines and alcohol use disorder: systematic review and meta-analysis","author":"Moura","year":"2022","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.conctc.2024.101333_bib65","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/NDT.S357797","article-title":"Levels of peripheral circulating IL-6 and IL-10 decrease over time despite high depression burden in PTSD patients","volume":"18","author":"Toft","year":"2022","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.conctc.2024.101333_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.phrs.2018.11.030","article-title":"Role of MCP-1 and CCR2 in alcohol neurotoxicity","volume":"139","author":"Zhang","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.conctc.2024.101333_bib67","doi-asserted-by":"crossref","first-page":"e0356","DOI":"10.1097\/MD.0000000000010356","article-title":"Early plasma monocyte chemoattractant protein 1 predicts the development of sepsis in trauma patients: a prospective observational study","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"1","key":"10.1016\/j.conctc.2024.101333_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44798-w","article-title":"Effect of alcohol on Brain-Derived Neurotrophic Factor (BDNF) blood levels: a systematic review and meta-analysis","volume":"13","author":"Shafiee","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.conctc.2024.101333_bib69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/08995605.2021.1976544","article-title":"Suicidal ideation, suicide attempts, and suicide death among Veterans and service members: a comprehensive meta-analysis of risk factors","volume":"34","author":"Schafer","year":"2022","journal-title":"Mil. Psychol."},{"issue":"6","key":"10.1016\/j.conctc.2024.101333_bib70","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatr."},{"issue":"3","key":"10.1016\/j.conctc.2024.101333_bib72","first-page":"125","article-title":"MDMA to treat PTSD in adults","volume":"51","author":"Latimer","year":"2021","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.conctc.2024.101333_bib73","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jpsychires.2021.02.061","article-title":"Subgroups of comorbid PTSD and AUD in U.S. military veterans predict differential responsiveness to two integrated treatments: a latent class analysis","volume":"137","author":"Panza","year":"2021","journal-title":"J. Psychiatr. Res."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865424000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865424000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T17:51:24Z","timestamp":1726681884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865424000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":71,"alternative-id":["S2451865424000802"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2024.101333","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2024.101333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101333"}}